Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(24 sites)
United States
Honor Health, Scottsdale, Arizona Arizona Cancer Center at University of Arizona, Tucson, Arizona Stanford Cancer Institute, Stanford University, Palo Alto, California University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California Sarcoma Oncology Center, Santa Monica, California Yale University School of Medicine, New Haven, Connecticut Johns Hopkins University, Sibley Memorial Hospital, Washington D.C., District of Columbia Florida Cancer Specialists, Lake Mary, Florida Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland Massachusetts General Hospital, Boston, Massachusetts Dana Farber Cancer Institute, Boston, Massachusetts M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota Washington University School of Medicine, St Louis, Missouri Memorial Sloan Kettering Cancer Center, New York, New York University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, Ohio Cleveland Clinic, Cleveland, Ohio Oregon Health and Science University, Portland, Oregon University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, Pennsylvania Sarah Cannon Research Institute, Nashville, Tennessee Vanderbilt Ingram Cancer Center, Nashville, Tennessee The University of Texas MD Anderson Cancer Center, Houston, Texas South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas University of Virginia, Charlottesville, Virginia University of Wisconsin, Carbone Cancer Center, Madison, Wisconsin